Evidence map›Paper›PMID 40384113›Full record

ArticleACS applied bio materials2025

Exploring the Anticancer Potential of Lamivudine-Loaded Polymeric Nanoparticles:

Natália Cristina Gomes-da-Silva, Alicia de Faria Almeida, Patrícia Severino, Mohammed Al-Qahtani, Luciana Magalhães Rebelo Alencar, Pierre Basílio de Almeida Fechine, Eduardo Ricci-Junior, Laura Fernanda Osmari Vendrame, João Augusto Pereira da Rocha, Solange Binotto Fagan and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS applied bio materials, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Natália Cristina Gomes-da-SilvaBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro 21941906, RJ Brazil.ORCID 0000-0002-9088-6671
Alicia de Faria AlmeidaBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro 21941906, RJ Brazil.
Patrícia SeverinoBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro 21941906, RJ Brazil.
Mohammed Al-QahtaniCyclotron and Radiopharmaceuticals Department, King Faisal Specialist Hospital and Research Center (KFSHRC), Riyadh 11564, Saudi Arabia.ORCID 0000-0002-3339-4232
Luciana Magalhães Rebelo AlencarBiophysics and Nanosystems Laboratory, Federal University of Maranhão, Department of Physics, São Luis 65065690, MA Brazil.ORCID 0000-0001-8210-2016
Pierre Basílio de Almeida FechineGrupo de Química de Materiais Avançados (GQMat), Departamento de Química Analítica e Físico-Química, Universidade Federal do Ceará-UFC, Campus do Pici, CP 12100, Fortaleza, 60451-970, CE Brazil.ORCID 0000-0002-7822-2354
Eduardo Ricci-JuniorFederal University of Rio de Janeiro, School of Pharmacy, Rio de Janeiro 21941900, RJ Brazil.
Laura Fernanda Osmari VendrameFranciscan University, Rua dos Andradas 1614, Santa Maria 97010-100, RS Brazil.
João Augusto Pereira da RochaFranciscan University, Rua dos Andradas 1614, Santa Maria 97010-100, RS Brazil.ORCID 0000-0002-3178-2362
Solange Binotto FaganFranciscan University, Rua dos Andradas 1614, Santa Maria 97010-100, RS Brazil.
Ralph Santos-OliveiraBrazilian Nuclear Energy Commission, Nuclear Engineering Institute, Laboratory of Nanoradiopharmacy and Synthesis of New Radiopharmaceuticals, Rio de Janeiro 21941906, RJ Brazil.ORCID 0000-0002-0905-481X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lamivudine is a synthetic nucleoside analogue to cytosine with a modified sugar moiety. It has potent action against Human Immunodeficiency Virus and chronic hepatitis. Recently, studies have also shown that lamivudine (3TC) can induce apoptosis in cancer cells and inhibit their proliferation, including breast cancer. We prepared polymeric nanoparticles using the double emulsification technique to incorporate polycaprolactone (PCL) as the polymer and lamivudine as the active compound. The nanoparticles were characterized by atomic force microscopy and dynamic light scattering. Then we carried out a full set of

Indexed as

Antineoplastic AgentsBiocompatible MaterialsLamivudineNanoparticlesAnimalsCell Line, TumorCell ProliferationCell SurvivalDrug Screening Assays, AntitumorFemaleHumansMaterials TestingMiceMolecular Dynamics SimulationParticle SizePolyestersAntineoplastic AgentsBiocompatible MaterialsLamivudinepolycaprolactonePolyestersnanotechnologyoncologyradiolabelingtherapytreatment

Identifiers

PMID40384113
PMCPMC12175167

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.